- In March 2022, researchers at The University of Hong Kong (HKU) developed a photo-responsive nanomedicine for targeted colorectal cancer therapy. The nanoparticles, created through the self-assembly of a near-infrared dye and a prodrug, are designed to target colon tumors after intravenous injection. Upon light irradiation, the nanoparticles release the drug to destroy cancer cells, with the entire process being monitored in real-time through in vivo imaging
- In January 2022, Pfizer Inc. and Acuitas Therapeutics entered into a development and option agreement, allowing Pfizer the option to license Acuitas' lipid nanoparticle (LNP) technology. This agreement covers up to ten targets for vaccine or therapeutic development on a non-exclusive basis. The collaboration aims to enhance Pfizer's capabilities in developing innovative treatments and vaccines using LNP technology
- In January 2021, Nanobiotix SA, a late-stage clinical biotechnology company, announced a collaboration with Sanofi through its subsidiary Curadigm. The partnership focuses on Curadigm's nano primer technology, which holds great promise for significantly advancing gene therapy development. This collaboration aims to enhance the effectiveness of gene therapies by leveraging the potential of nano primer technology to improve treatment outcomes
- In May 2021, Nanobiotix SA, a late-stage clinical biotechnology company, formed a strategic partnership with LianBio, a biotechnology firm focused on China and major Asian markets. The collaboration is aimed at developing and commercializing Nanobiotix's lead product candidate, NBTXR3, a potential first-in-class radioenhancer. This partnership covers Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore, and Thailand, with the goal of expanding the reach of this promising treatment across the region
